Bevacizumab Improves Survival in Metastatic Breast Cancer
 

Treatment with the combination of bevacizumab (Avastin) and chemotherapy improved progression-free survival (PFS) and overall survival (OS) in women with HER2-negative metastatic breast cancer, according to two phase III studies being presented at the 2014 ESMO Congress later this week.

http://www.onclive.com/conference-co...-Breast-Cancer